U.S. Stock Market Midday Update
InflaRx NV rose 14.37%. Based on recent key news:
<ol>
<li>
On April 27, InflaRx successfully regained compliance with Nasdaq's minimum bid price, eliminating potential delisting risks. Nasdaq notified InflaRx that its stock had closed at or above $1 for 10 consecutive trading days from April 13 to April 24. This compliance matter is now resolved, driving the stock price up.
</li>
<li>
On April 28, InflaRx announced that it had received written notification from the Nasdaq market confirming its compliance with the minimum bid price requirement. This update indicates positive developments regarding the company's stock position.
</li>
<li>
On April 29, InflaRx reaffirmed its compliance with Nasdaq's minimum bid price requirement, further bolstering market confidence. The biopharmaceutical industry has shown strong performance recently.
</li>
</ol>
Stocks with High Trading Volume in the Industry
KalVista Pharmaceuticals rose 38.72%. Based on recent key news:
<ol>
<li>
On April 29, Italy's Chiesi Group announced the acquisition of KalVista Pharmaceuticals for $1.9 billion. This deal includes debt and is being paid in cash at $27 per share, a 36% premium over the average stock price in the past month. This news significantly boosted KalVista's stock price by 38.6%. Source: Reuters
</li>
<li>
On April 29, Chiesi Group stated that this acquisition will strengthen its strategic position in the rare disease sector and expand its commercial footprint in the U.S. KalVista's main product, EKTERLY, is an oral medication for treating hereditary angioedema, which has been approved in multiple markets. Source: Financial Associated Press
</li>
<li>
On April 30, KalVista Pharmaceuticals' stock price rose significantly following Chiesi Group's acquisition proposal, with the market responding positively to the deal, further driving the stock price up. Source: CNBC The rare disease sector is active in mergers and acquisitions, attracting high market attention.
</li>
</ol>
AbbVie rose 3.51%. Based on recent key news:
<ol>
<li>
On April 29, AbbVie reported first-quarter results that exceeded expectations, with adjusted earnings per share of $2.65, higher than the market expectation of $2.59, driving the stock price up. The company also raised its full-year adjusted earnings per share forecast for 2026 to $14.08 to $14.28. Source: Barron's
</li>
<li>
On April 29, AbbVie's immunology product portfolio performed strongly, with sales of Skyrizi and Rinvoq increasing by 31% and 23%, respectively, contributing to an overall revenue growth of 12% to $15 billion, surpassing analyst expectations. Source: RTTNews
</li>
<li>
On April 29, analysts maintained a &#34;Buy&#34; rating on AbbVie, predicting that its stock price could reach $253.50 within the next 12 months, representing a 28.2% upside from the current price. Source: Reuters Strong demand for immunology products drives performance growth
Regeneron Pharmaceuticals fell 6.74%. Based on recent news,
</li>
<li>
On April 29, Regeneron Pharmaceuticals announced its first-quarter financial report, with an adjusted earnings per share of $9.47, exceeding the expected $8.94, and sales reached $3.61 billion, a year-on-year increase of 19%. Despite strong performance, the stock price fell due to a 7% quarter-on-quarter decline in net product sales of Eylea HD, attributed to low inventory levels.
</li>
<li>
On April 29, Regeneron Pharmaceuticals announced a new $3 billion stock repurchase plan. Although this news typically boosts stock prices, the market expressed concerns about the company's future profitability and cost control, leading to a decline in stock price.
</li>
<li>
On April 30, Regeneron Pharmaceuticals projected a GAAP gross margin of 77%-78% for the fiscal year 2026, down from the previous 79%-80%. Adjusted R&amp;D expenses are expected to be between $5.9 billion and $6.1 billion, and non-GAAP selling and administrative expenses are expected to be between $2.5 billion and $2.65 billion. Increased costs raised market concerns, resulting in a drop in stock price. The pharmaceutical industry as a whole performed strongly, with significant impacts from policy changes.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Amgen fell 0.35%, with increased trading volume. Based on recent key news:
<ol>
<li>
On April 28, the U.S. FDA proposed to withdraw Amgen's approval for the rare disease drug Tavneos, citing that the drug failed to demonstrate its effectiveness and that there were false or concealed data in the application. This news led to a decline in Amgen's stock price.
</li>
<li>
On April 28, the FDA warned that Tavneos could cause severe liver damage, including rare but serious vanishing bile duct syndrome (VBDS), and reported eight cases of death. This further heightened market concerns about Amgen.
</li>
<li>
On April 29, analysts generally rated Amgen's stock as a hold and noted that five other stocks were considered better investment choices, weakening market confidence in Amgen. The FDA's questioning of Tavneos's safety and efficacy impacted market confidence
</li>
</ol>

IFRX

InflaRx NV rose 14.37%; KalVista Pharmaceuticals rose 38.72%, with a transaction volume of USD 1.566 billion; AbbVie rose 3.51%, with a transaction volume of USD 1.471 billion; Regeneron Pharmaceuticals fell 6.74%, with a transaction volume of USD 849 million; Amgen fell 0.35%, with a market value of USD 182.6 billion

Price Alert

InflaRx NV

U.S. stock market mid-session update: InflaRx up 14.37%, successfully restored Nasdaq compliance, market confidence greatly increased!